AMSSM scientific statement concerning viscosupplementation injections for knee osteoarthritis: importance for individual patient outcomes

Thomas H Trojan,1 Andrew L Concoff,2 Susan M Joy,3 John R Hatzenbuehler,4 Whitney J Saulsberry,5 Craig I Coleman6

ABSTRACT

Osteoarthritis (OA) is a disabling disease that produces severe morbidity reducing physical activity. Our position statement on treatment of knee OA with viscosupplementation injection (hyaluronic acid, HA) versus steroid (intra-articular corticosteroids, IAS) and placebo (intra-articular placebo, IAP) is based on the evaluation of treatment effect by examining the number of participants within a treatment arm who met the Outcome Measures in Rheumatoid Arthritis Clinical Trials-Osteoarthritis Research Society International (OMERACT-OARSI) criteria, which is different and more relevant than methods used in other reviews which examined if the average change across the treatment groups were clinically different. We performed a systematic literature search for all relevant articles from 1960 to August 2014 in the MEDLINE, EMBASE and Cochrane CENTRAL. We performed a network meta-analysis (NMA) of the relevant literature to determine if there is a benefit from HA as compared with IAS and IAP. 11 papers met the inclusion criteria from the search strategy. On NMA, those participants receiving HA were 15% and 11% more likely to respond to treatment by OMERACT-OARSI criteria than those receiving IAS or IAP, respectively (p<0.05 for both). In the light of the aforementioned results of our NMA, the American Medical Society for Sport Medicine recommends the use of HA for the appropriate patients with knee OA.

INTRODUCTION

Osteoarthritis (OA) is a disabling disease that produces severe morbidity reducing physical activity.1 2 The purpose of this statement is to provide an evidence-based, best practices summary to assist physicians with the non-operative treatment of OA and to establish the level of evidence, knowledge gaps and areas requiring additional research. The American Medical Society for Sport Medicine (AMSSM) represents over 2100 non-surgical sports medicine physicians who have completed additional training in sports medicine after a residency programme in family medicine, internal medicine, paediatrics, emergency medicine, or physical medicine and rehabilitation, many of whom have extended expertise in OA evaluation and management. AMSSM is committed to development and maintenance of a strong relationship with our patients and communities through high-quality patient-centred care.

OA is one of the leading causes of disability in adults in the USA,1 and knee OA specifically is ranked within the top 10 non-communicable diseases for global disability-adjusted life years.3 In 2005, arthritis-related conditions represented the second most common reason for medical visits, and it was the fifth most expensive inpatient condition in the USA for 2008.4 The lifetime risk of suffering symptomatic knee OA is estimated to be 44.7% (95% CI 40.0% to 49.3%)4 and approximately 1 in 11 of the US population is diagnosed with symptomatic knee OA by age 60 years.5

Knee arthritis compromises physical activity, thus contributing to rising obesity, type 2 diabetes mellitus and general chronic disease, thereby markedly escalating healthcare expenditures.6 Patients with knee OA have a significantly poorer quality of life when compared with healthy controls.6 The dose–response relationship between weight and arthritis pain underscores the importance of managing pain to improve activity level in those afflicted with knee OA.4

There is general consensus that the initial management of knee OA treatment should include weight loss and strengthening exercises.7 However, certain aspects of treatment for knee OA are controversial. Other societies have recommended against, supported the use or considered the data inconclusive concerning the use of viscosupplementation.8–10 Many physicians have seen patients with OA experience clinical benefit following hyaluronic acid (HA) injections while others have not.11

Our position statement on the treatment of knee OA with viscosupplementation injection versus placebo and steroid is based on the evaluation of treatment effect by examining the number of participants within a treatment arm who met the Outcome Measures in Rheumatoid Arthritis Clinical Trials-Osteoarthritis Research Society International (OMERACT-OARSI) criteria which is different and more relevant than methods used in other reviews which examined if the average change across the treatment groups was clinically different.12 13 We believe it is important to look at the potential of an individual to improve due to a treatment given by injection when compared to the potential for improvement due to a treatment given by another therapeutic or placebo injection. We performed a network meta-analysis (NMA) of the relevant literature to determine if there is a benefit from high-molecular weight and/or low-molecular weight HA as compared to intra-articular corticosteroids (IAS) and intra-articular placebo (IAP). To do so, we compared the percentage of individuals with knee OA who achieved improvement as defined by the OMERACT-OARSI responder criteria13 among those treated with HA, IAS or placebo injection.
METHODS
Data sources and searches
We performed a systematic literature search for all relevant articles from 1960 to August 2014 in the MEDLINE, EMBASE and Cochrane CENTRAL. The search strategy combined the Medical Subject Heading (MeSH) and keywords for viscosupplementation, HA, IAS and OA. Our MEDLINE search strategy can be found in online supplementary appendix 1. In addition, we performed a manual search of references from reports of randomised controlled trials (RCTs), prior meta-analyses and review articles to identify additional relevant studies. All relevant articles referenced in the American Academy of Orthopaedic Surgeons (AAOS) Treatment of Osteoarthritis of the Knee Evidence-Based Guidelines were also reviewed. The results of identified studies were supplemented with data identified through the grey literature including regulatory agency reports, http://www.clinicaltrials.gov, and contacting investigators for clarification or additional data. Two investigators reviewed each potentially relevant citation independently.

Study selection
To be included in this meta-analysis, studies had to: (1) be in English; (2) be an RCT with patients with knee OA; (3) evaluate the efficacy of either IAS or intra-articular HA (regardless of molecular weight) to placebo/no treatment (control) or each other and (4) report on the OMERACT-OARSI responder rates or mean change from baseline in the Western Ontario and McMaster University Arthritis Index (WOMAC) pain, stiffness or function subscales after at least 8 weeks following the last injection and no longer than 26 weeks. Studies comparing one of the aforementioned therapies to tidal irrigation or arthroscopic lavage were excluded, as these therapies were not deemed to be inactive (a true control).

Validity assessment
Two independent investigators assessed the quality of each included RCT using the Cochrane Risk of Bias Tool. This checklist includes six quality questions encompassing the following domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome reporting and selective reporting. Each item was scored as a low, unclear or high risk of bias.

Data extraction
Two investigators used a standardised tool to independently extract all data with disagreements resolved by discussion or a third investigator. The data were extracted for each RCT: (1) author identification; (2) year of publication; (3) study design and methodological quality information needed to complete the Cochrane Collaboration’s tool for assessing risk of bias; (4) sample size; (5) inclusion/exclusion criteria; (6) baseline characteristics; (7) HA (and molecular weight) and corticosteroid doses and schedules used and (8) duration of follow-up.

End point data collected included the OMERACT-OARSI responder rate and mean change from baseline WOMAC pain, stiffness and function subscale scores. When an end point was reported at multiple time points between 8 and 26 weeks, we chose the time of optimal response to active therapy. The OMERACT-OARSI response was defined as having an improvement in WOMAC pain or WOMAC function ≥50% and absolute change ≥20 mm on the 100 mm visual analogue scale (VAS) or improvement in at least 2 of the 3 following categories: pain ≥20% and absolute change ≥10 mm; and/or patient’s global assessment ≥20% and absolute change ≥10 mm. The WOMAC index is a standardised and validated methodology for assessing pain associated with OA, and is routinely used as a primary end point in clinical trials studying the effect of drugs and devices for OA. It is self-administered and consists of three domains pain (5 items), stiffness (2 items) and physical function (17 items) measured on a Likert scale (score 0–5) or on a 100 mmVAS, with higher value indicating more severe symptoms. In cases where more than 1 published time point on the same study population was available in multiple publications, the most comprehensive article and the primary end point time point of best response (between 8 and 26 weeks) were used in the meta-analysis in order to optimise the amount of analysable data.

Statistical analysis
We performed traditional pairwise meta-analyses analysing mean change from baseline in WOMAC pain, stiffness and function subscale scores as continuous variables using StatsDirect V2.7.8 (StatsDirect Ltd, Cheshire, UK). Pairwise meta-analyses were performed for each therapy, combining data from approved doses of the same therapies using the method recommended by the Cochrane Collaboration. For these continuous end points, standardised mean differences (SMDs) as Hedges’ g and associated 95% CIs were calculated using a random-effects approach. In instances where variances for net changes were not reported directly, they were calculated from CIs, p values or individual variances. If the variances for paired differences were not reported, we calculated it from variances at baseline and at the end of follow-up, assuming a correlation coefficient of 0.5 between initial and final values. The OMERACT-OARSI responder rate was meta-analysed using a random-effects model as a dichotomous end point with weighted averages reported as relative risks (RRs) and associated 95% CIs. For all pairwise meta-analyses containing at least three studies, the likelihood of statistical heterogeneity (using the I² statistic with a value >50% representing important statistical heterogeneity) and publication bias (using Egger’s weighted regression statistic with a p<0.05 suggesting a higher likelihood of publication bias) was assessed. We then performed NMA, a generalisation of traditional pairwise meta-analysis that compares all pairs of treatments within a set of treatments for the same disease state (in this case OA of the knee). Along with analysing direct within-trial comparisons between two treatments, the NMA framework enables incorporation of indirect comparisons constructed from two trials that have one treatment in common. This type of analysis safeguards the within-trial randomised treatment comparison of each trial while combining all available comparisons between treatments.

We used the package ‘netmeta’ (V0.5–0) in R (V3.0.2, The R Foundation for Statistical Computing). The package uses a novel graph theory methodology that exploits the analogy between treatment networks and electrical networks to construct an NMA model accounting for the correlated treatment effects in multivariable trials. We implemented a random-effects model assuming common heterogeneity across all comparisons. Inconsistency was assessed by comparing the results from direct and indirect estimates of effect. Incoherence was said to be present if direct and indirect evidence estimates varied to a statistically significant extent as depicted by a test for interaction.

RESULTS
Eleven papers met the inclusion criteria from the search strategy (see online supplementary appendix 1). The average age of


Consensus statement
the participants in the studies included in this analysis was over 60 years (table 1). In most studies, the participants’ severity was Kellgren-Lawrence grade 2 or 3. The average body mass index of the participants in all studies was categorised as overweight or obese. Most studies followed the participants for a total duration of 6 months or the equivalent 26 weeks, with one at 12 weeks and one at 18 weeks. The number of injections varied from a single dose to 5 weekly injections depending on the preparation. The sample size of all but one study was more than 200 with a maximum of 588 participants with a mean of 336 participants. Females were subjects in the studies more often than males.

Cochrane bias tool assessment (table 2) demonstrated that most studies exhibited a lower risk of bias for the majority of domains assessed. When potential for bias was present among studies, it was most commonly due to incomplete data reporting, selective reporting or the absence of blinding of participants and personnel. For evaluable analyses, Egger’s p values suggested a lower likelihood of publication bias (Egger’s p>0.05 for all).

On NMA (table 3), those patients receiving HA were 15% and 11% more likely to respond to treatment by the OMERACT-OARSI criteria than those receiving IAS or IAP respectively (p<0.05 for both), while IAS use was not associated with an improved OARSI responder rate. HA significantly decreased WOMAC pain and function scores compared to control, and WOMAC function scores compared to IAS. HA trended towards improving WOMAC stiffness scores compared to control and IAS; however, statistical significance was not reached for this analysis. No significant reduction in WOMAC pain, stiffness or function scores were observed with IAS compared to control. The median optimal timing used in this analysis was OARSI: 26 weeks (13–26 weeks), WOMAC pain: 25 weeks (13–26 weeks), WOMAC function: 13 weeks (12–26 weeks) and WOMAC stiffness: 13 weeks (13–26 weeks).

Moderate degrees of statistical heterogeneity were observed in the HA versus control WOMAC pain, stiffness and function analyses (I²=49%, 55% and 51%, respectively), while minimal heterogeneity was observed in the HA versus control OARSI responder analysis. All other analyses had too few direct comparisons to assess statistical heterogeneity. On comparison of available direct and indirect estimates of effect, no statistically significant incoherence was noted.

Safety concerns about the HA products were evaluated in the studies. The most common side effect was arthralgia, swelling and stiffness that occurred in equivalent percentages in each treatment and control group. One study had a significant difference in arthralgia of 17% in HA and 3.2% in IAS with resolution symptoms within 2–3 weeks. The other studies did not demonstrate a difference between HA and control in treatment-related adverse events (table 4).

**DISCUSSION**

We conducted an NMA of the efficacy of intra-articular injection of HA versus IAS and IAP injections in knee OA. To the best of our knowledge, this is the first study to employ an NMA to assess the effectiveness of HA injections for knee OA through comparison of OMERACT-OARSI responder rates. Our results demonstrate evidence of a small but statistically significant improvement for the group of participants treated with HA injections compared to those treated with IAS or IAP injections with regard to pain and function as assessed by the relevant WOMAC subscales.

Furthermore, on an individual level, our results indicate that HA instillation led to a 15% and 11% greater chance of achieving OARSI responder status than did IAS and IAP, respectively, each statistically significant. The OMERACT-OARSI criteria were developed in 2003 in order to standardise the assessment of which individuals in clinical trials for knee OA demonstrate a significant clinical response as a consequence of one or more treatment interventions. As such, by its very definition, statistically significant changes in OMERACT-OARSI responder rates represent clinically significant differences. Thus, the statistically significant results that we have identified for HA versus IAS and IAP also represent a clinically relevant difference.

We found no statistical or clinical benefit for IAS versus IAP injection, despite using the time point of maximal IAS benefit for comparison with IAP. Similarly, we were unable to identify significant differences in treatment response when comparing the efficacy of low versus high molecular weight HA products compared to IAP injection, a finding that was influenced by the limitation in power imposed by the paucity of studies of adequate quality to compare the effects of products of different molecular weights.

Our results of statistically significant benefits of HA injections over IAP injections are consistent with several of the prior meta-analyses of HA injections for knee OA. When analysed in terms of mean rather than individual responses, the small effect size in our study (0.2) was also consistent with the majority of prior studies, except for one study with a smaller effect size. By way of context, the effect size identified by our study, although small, is similar to that found in a meta-analysis of non-steroidal anti-inflammatory drugs (NSAIDs) for knee OA. The interpretation of the clinical relevance of the small, statistical benefit has varied among reviews and has been considered controversial. Accordingly, our interpretation of the data, specifically our OMERACT-OARSI results reflecting the superiority of HA injections over IAS and IAP, concurs with certain prior reviews by demonstrating a meaningful clinical correlation to the statistical benefit from HA injections, while not with other studies that have interpreted the data as reflecting no clinical benefit. The divergent conclusions from prior studies have been attributed to the varied methodology employed in study selection, the assessment of effect size, and the interpretation of the clinical relevance of the statistical results.

Furthermore, the relatively large and persistent placebo effects found in trials of knee OA in general, but particularly seen among trials employing intra-articular saline controls, have been recognised as substantial barriers to OA therapeutics, including viscosupplements. In fact, given that arthrocentesis with or without a saline injection has been recognised as an effective intervention in patients with knee OA presenting with a significant knee effusion, some researchers have suggested that intra-articular saline ‘placebo’ injections might better be categorised as active controls rather than as ‘placebos’. As a consequence of the uncertainty generated by these issues, when the results of prior systematic reviews and meta-analyses have been used to generate evidence-based guidelines for the treatment of knee OA, recommendations regarding the use of HA injections have typically been measured.

Thus, in their latest iterations, the American College of Rheumatology makes no official recommendation for the use of HA injections and the OARSI guidelines rate the benefit from HA as uncertain. A notable exception to this trend was the recent guideline published by the AAOS which changed its prior recommendation regarding the use of HA injections for knee OA from ‘inconclusive’ to ‘strongly recommending against’
its use. Of note, the latest AAOS review demonstrated the statistically significant benefits of HA injections on the WOMAC pain, stiffness and function subscales that have been noted in most other reviews, including the prior AAOS review. The AAOS panel strongly recommended against the use of HA injections based on a re-evaluation of the existing literature according to a change in the analytic method by which clinical relevance was assessed.

The guideline relied on a relatively new outcome measure, the minimum clinical important improvement (MCII). The MCII and a closely related concept that relates either improving or worsening the minimal clinically important difference (MCID)\(^3^9\) represent an effort by investigators to incorporate participants’ expectations for improvement from a given intervention into the assessment of its efficacy.\(^3^9\)\(^4^0\) Although these outcome measures are recognised as an important innovation for use in assessing the clinical relevance of statistical results in OA research trials, the methodology applied in certain guidelines has been criticised on several accounts.\(^4^1\) It should be noted that the MCII has not been adequately validated for use in isolation to guide clinical decision-making.\(^2\) Further, the application of the MCII in some guidelines does not appear to account for the variance in MCII by baseline symptom severity,\(^3^9\) treatment type,\(^4^2\) age and trial assessment intervals.\(^4^3\) Thus, when the AAOS investigators used studies of NSAIDs and rehabilitation to generate a single cut-off value to assess MCII responses to HA injection with placebo controlled between group comparisons, the cut-off values to assess the MCII as a determinant of HA efficacy may have been higher than the appropriate level, thus biasing the results towards fewer studies

**Table 1** Studies included in the analysis

<table>
<thead>
<tr>
<th>Study</th>
<th>Sample size</th>
<th>Mean age</th>
<th>Percentage of female</th>
<th>Mean BMI (kg/m(^2))</th>
<th>Severity</th>
<th>Product</th>
<th>Control</th>
<th>Number of injections</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Altman et al(^1^7)</td>
<td>346</td>
<td>63.1</td>
<td>46 vs 64</td>
<td>29.9</td>
<td>K-L II-IV</td>
<td>NASHA (Durolane)</td>
<td>Saline</td>
<td>1</td>
<td>26 weeks</td>
</tr>
<tr>
<td>Altman et al(^1^8)</td>
<td>588</td>
<td>61.6</td>
<td>63</td>
<td>32.7</td>
<td>K-L II-III</td>
<td>BioHA</td>
<td>Saline</td>
<td>3</td>
<td>26 weeks</td>
</tr>
<tr>
<td>Caborn et al(^1^9)</td>
<td>216</td>
<td>63.1</td>
<td>56.9</td>
<td>31</td>
<td>Not reported</td>
<td>Hylan G-F 20 (Synvisc)</td>
<td>Triamcinolone hexacetonide</td>
<td>3, 1</td>
<td>26 weeks</td>
</tr>
<tr>
<td>Chevalier et al(^2^0)</td>
<td>253</td>
<td>62.9</td>
<td>74 vs 68</td>
<td>27.9</td>
<td>Reported Height and weight not BMI but needed to be below 40</td>
<td>K-L II-III</td>
<td>Hylan G-F 20 (Synvisc)</td>
<td>Saline</td>
<td>1</td>
</tr>
<tr>
<td>Day(^5)</td>
<td>240</td>
<td>62</td>
<td>56 (HA) vs 61 (P)</td>
<td></td>
<td>Mild to Moderate; &lt;K-L IV</td>
<td></td>
<td>2.5 mL of the PBS vehicle (batch number C4F27S)</td>
<td>5</td>
<td>18 weeks</td>
</tr>
<tr>
<td>DeCaria et al(^2^2)</td>
<td>30</td>
<td>72.4</td>
<td>47</td>
<td>29.9</td>
<td>K-L III</td>
<td>HA 20 mg/mL</td>
<td>HA 0.001 mg/mL</td>
<td>3</td>
<td>6 months</td>
</tr>
<tr>
<td>Housman(^1^9)</td>
<td>391</td>
<td>60.9</td>
<td>71 vs 61 vs 69</td>
<td>31.2</td>
<td>K-L III</td>
<td>Hylan G-F 20 (Synvisc)</td>
<td>IAS</td>
<td>2, 1</td>
<td>26 weeks</td>
</tr>
<tr>
<td>Huang et al(^2^3)</td>
<td>200</td>
<td>65</td>
<td>76</td>
<td>25.6</td>
<td>K-L II-III</td>
<td>Hyalgan</td>
<td>Saline</td>
<td>5</td>
<td>26 weeks</td>
</tr>
<tr>
<td>Leighton et al(^2^4)</td>
<td>442</td>
<td>61.7</td>
<td>51 vs 47</td>
<td>28.3</td>
<td>K-L III</td>
<td>NASHA (Durolane)</td>
<td>MPA</td>
<td>1</td>
<td>12 weeks</td>
</tr>
<tr>
<td>Navarro-Sarabia et al(^2^5)</td>
<td>306</td>
<td>63.5</td>
<td>83.7</td>
<td>28.4 vs 28.7</td>
<td>K-L III</td>
<td>1% Sodium hyaluronate</td>
<td>Saline</td>
<td>5</td>
<td>40 months</td>
</tr>
<tr>
<td>Strand et al(^2^6)</td>
<td>379</td>
<td>60.6</td>
<td>59.5 vs 60.2</td>
<td>28.5</td>
<td>K-L I-III</td>
<td>Gel-200</td>
<td>Saline</td>
<td>1</td>
<td>13 weeks</td>
</tr>
</tbody>
</table>

BMI, body mass index; HA, hyaluronic acid; IAS, intra-articular corticosteroids; MPA, methylprednisolone acetate; PBS, phosphate buffered saline.

**Table 2** Cochrane bias rating

<table>
<thead>
<tr>
<th>Study</th>
<th>Random sequence generation</th>
<th>Allocation concealment</th>
<th>Blinding of participants and personnel</th>
<th>Blinding of outcome assessment</th>
<th>Incomplete outcome data</th>
<th>Selective reporting</th>
</tr>
</thead>
<tbody>
<tr>
<td>Altman et al(^1^7)</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>?</td>
</tr>
<tr>
<td>Altman et al(^1^8)</td>
<td>+</td>
<td>?</td>
<td>?</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Caborn et al(^1^9)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Chevalier et al(^2^0)</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Day et al(^2^1)</td>
<td>+</td>
<td>?</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>?</td>
</tr>
<tr>
<td>Decaria et al(^2^2)</td>
<td>+</td>
<td>?</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Housman et al(^1^9)</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Huang et al(^2^3)</td>
<td>?</td>
<td>?</td>
<td>?</td>
<td>?</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Leighton et al(^2^4)</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>?</td>
</tr>
<tr>
<td>Navarro-Sarabia et al(^2^5)</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>?</td>
</tr>
</tbody>
</table>

Two recent studies \[45,46\] support the absence of HA injections, although a recent meta-analysis of these treatments through the use of an NMA and has reached its recommendations for IAS and HA injections. Unlike the AAOS document seems to lack internal consistency with regard to its recommendations for IAS and HA injections. Furthermore, the AAOS study, our study design allowed a direct comparison of these treatments through the use of an NMA and has reached different conclusions.

A strong recommendation against the use of an HA injection is not without consequence, since individual patients find benefit from HA injections, as we demonstrate in this paper. An incorrect recommendation against the use of HA may encourage third party payers to limit or eliminate reimbursement for HA as a cost-saving measure. (See commentary in Washington State Health Care Authority, Health Technology Assessment. “Hyaluronic Acid/Viscosupplementation Draft Evidence Report: Public Comment & Response” (accessed online 15 Feb 2015) https://hca.wa.gov/hta/Documents/ha-visco_final_report_101113.pdf.) Furthermore, given the limited armamentarium of non-operative interventions available to treat symptomatic knee OA and that HA injections are typically reserved for those patients who are unresponsive to first-line, lifestyle interventions including exercise, weight loss and oral medications, it is possible that an increase in the number of surgical procedures may result, in the absence of HA injections, although a recent meta-analysis of this question was inconclusive. \[45\] Two recent studies \[44,46\] supported with funding from the Agency for Healthcare Research and Quality (ARHQ) have investigated questions related to the efficacy of HA on knee OA that differ from the focus of our research. Bannaru et al. \[46\] performed the only other NMA of HA in knee OA use of which we are aware as part of a more global investigation of non-operative treatment options. Though OMERACT-OARSI responder rates were not investigated, the results obtained with regard to HA injections are consistent with those we report. Specifically, HA injections demonstrated statistically significant benefit when prespecified criteria were met for clinical significance, which with regard to pain demonstrated the largest effect size (0.63, CI 0.39 to 0.88) of any treatment tested. These investigators also noted greater improvement in response to intra-articular injections, including HA injections, than from oral treatments, and statistically significant improvements from HA injections in function when compared to IAS and IAP and stiffness when compared to IAP. Contrarily, another recent ARHQ-funded review, \[43\] which specifically targeted the population of severe OA of the knee, found no functional benefit from HA injections and insufficient evidence to assess delay or avoidance of total knee replacement as a benefit of HA injections. Of note, the methodology of this latter ARHQ-funded study differs from ours in the impact of HA injection on pain, the most frequently assessed outcome parameter. This was suggested by the limited magnitude of the mean changes seen across groups in contrast to the more substantial changes we have demonstrated in individual responsiveness by OARSI responder criteria. It would appear that certain individuals respond more robustly than others to HA injection. Such variation in individual response has also been recognised for IAS injections. \[47\] Numerous clinical parameters including subject age, \[30\] the presence \[30\] or absence \[30\] of effusion, higher baseline function, \[51\] synovial fluid HA concentration, \[52\] and certain structural measures (eg, the severity \[30\] or location of joint damage \[30\] ) have been suggested to improve an individual’s responsiveness to injection. However, efforts to prospectively identify a set of clinical parameters that predict a favourable response to HA injection have been unsuccessful to date. \[49\] Furthermore, when assessing the value of HA injections for knee OA, the magnitude of symptomatic benefit may not be the only criterion on which recommendations should be made. For instance, even among those without significant symptomatic improvement, HA

### Table 3

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Comparison</th>
<th>NMA ES (95% CI)</th>
<th>Number of studies</th>
<th>TMA ES (95% CI)</th>
<th>I² (%)</th>
<th>Egger’s p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>WOMAC pain</td>
<td>HA vs CONT</td>
<td>−0.19 (−0.32 to −0.06)</td>
<td>7</td>
<td>−0.19 (−0.32 to −0.06)</td>
<td>48.9</td>
<td>0.26</td>
</tr>
<tr>
<td></td>
<td>HA vs IAS</td>
<td>−0.06 (−0.28 to 0.16)</td>
<td>2</td>
<td>−0.06 (−0.28 to 0.17)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>IAS vs CONT</td>
<td>−0.13 (−0.39 to 0.13)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>WOMAC stiffness</td>
<td>HA vs CONT</td>
<td>−0.12 (−0.27 to 0.03)</td>
<td>6</td>
<td>−0.12(−0.27 to 0.03)</td>
<td>55.1</td>
<td>0.51</td>
</tr>
<tr>
<td></td>
<td>HA vs IAS</td>
<td>−0.17 (−0.50 to 0.16)</td>
<td>1</td>
<td>−0.17 (−0.36 to 0.01)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>IAS vs CONT</td>
<td>0.05 (−0.31 to 0.41)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>WOMAC function</td>
<td>HA vs CONT</td>
<td>−0.19 (−0.32 to −0.05)</td>
<td>7</td>
<td>−0.19 (−0.32 to −0.05)</td>
<td>50.8</td>
<td>0.38</td>
</tr>
<tr>
<td></td>
<td>HA vs IAS</td>
<td>−0.29 (−0.53 to −0.05)</td>
<td>2</td>
<td>−0.30 (−0.58 to −0.01)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>IAS vs CONT</td>
<td>−0.10 (−0.18 to 0.38)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>OARSI responder</td>
<td>HA vs CONT</td>
<td>1.11 (1.01 to 1.20)</td>
<td>4</td>
<td>1.10 (1.01 to 1.19)</td>
<td>0</td>
<td>0.27</td>
</tr>
<tr>
<td></td>
<td>HA vs IAS</td>
<td>1.15 (1.02 to 1.30)</td>
<td>2</td>
<td>1.15 (1.01 to 1.30)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>IAS vs CONT</td>
<td>0.96 (0.82 to 1.11)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

Likelihood of statistical heterogeneity (I² statistic with a value >50% representing important statistical heterogeneity) and publication bias (Egger’s weighted regression statistic with a p<0.05 suggesting a higher likelihood of publication bias). CONT, control; HA, hyaluronic acid; HMW, high molecular weight; IAS, intra-articular corticosteroids; LMW, low molecular weight; NA, not applicable; NMA, network meta-analysis; TMA, traditional meta-analysis.


Downloaded from http://bjsm.bmj.com/ on April 5, 2017 - Published by group.bmj.com
<table>
<thead>
<tr>
<th>Study</th>
<th>Sample size</th>
<th>Severity</th>
<th>Product (HA)</th>
<th>Control (Sa, IAS)</th>
<th>Number of injections</th>
<th>Duration</th>
<th>AEs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Altman et al</td>
<td>346</td>
<td>K-L II-IV</td>
<td>NAHA (Durolane)</td>
<td>Saline (Sa)</td>
<td>1</td>
<td>26 weeks</td>
<td>Treatment-related AEs: HA=12.8% vs S=8.0%; arthralgia: HA=6.4% vs Sa=2.9%; &gt;70% of treatment-related AEs reported within 2 days in both treatment groups; 9 treatment-related AEs led to withdrawal (HA=5, S=4), 1 worsening knee OA pain (HA), 1 knee synovitis (S); no serious treatment-related AEs</td>
</tr>
<tr>
<td>Altman et al</td>
<td>588</td>
<td>K-L II-III</td>
<td>BioHA</td>
<td>Saline (Sa)</td>
<td>3</td>
<td>26 weeks</td>
<td>Treatment-related AEs: HA=10% vs S=11%; arthralgia: HA=9% vs Sa=12%; 8 treatment-related AEs led to withdrawal (HA=3, Sa=3); no joint effusions in treatment group</td>
</tr>
<tr>
<td>Caborn et al</td>
<td>216</td>
<td>Not reported</td>
<td>Hylan G-F 20 (Synvisc)</td>
<td>Triamcinolone hexacetonide (IAS)</td>
<td>3, 1</td>
<td>26 weeks</td>
<td>No statistically significant differences observed between treatment groups for overall incidence of adverse events or IAS incidence of any single adverse event; majority of adverse events reported were not considered to be related to the study treatments; number and severity of local injection-site reactions comparable between treatment groups; injection site-related events HA=7% vs IAS=10% (p=0.224); swelling related events HA=8% vs IAS=12% (p=0.136); discontinuation due to adverse events HA=10% vs IAS=10%; 9 serious adverse events in 6 patient in IAS group considered not to be treatment related</td>
</tr>
<tr>
<td>Chevalier et al</td>
<td>253</td>
<td>K-L II-III</td>
<td>Hylan G-F 20 (Synvisc)</td>
<td>Saline (Sa)</td>
<td>1</td>
<td>26 weeks</td>
<td>No target knee serious AEs; no treatment related serious AEs; incidence of AEs HA=5.7% vs S=3.1% (p=0.366); no difference in treatment-related AEs (p=0.203) or procedure-related target knee AEs (p=0.531), all of which were mild or moderate</td>
</tr>
<tr>
<td>Day et al</td>
<td>240</td>
<td>Mild to Moderate; &lt;K-L IV</td>
<td>25 mg of sodium HA in 2.5 mL of phosphate buffered saline (ARTZTM; batch no. C4F275). The sodium HA was extracted from rooster combs and the purified material has a molecular weight of 6.2 to 11.7×10^5 Da</td>
<td>2.5 mL of the Buffered saline (Sa) (batch no. C4F285)</td>
<td>5</td>
<td>18 weeks</td>
<td>Treatment-related adverse events type and incidence between the active and control groups was similar. The most frequent adverse event was injection site pain (HA group 16; controls 13); dropout was 4% HA and 6% control</td>
</tr>
<tr>
<td>DeCaria et al</td>
<td>30</td>
<td>K-L II-III</td>
<td>HA 20 mg/mL</td>
<td>HA 0.001 mg/mL</td>
<td>3</td>
<td>6 months</td>
<td>No significant AEs reported; limited number of patients reported minor discomfort during the injection process</td>
</tr>
<tr>
<td>Housman et al</td>
<td>391</td>
<td>K-L II-III</td>
<td>Hylastan 2, 1</td>
<td>Methylprednisone acetate (IAS)</td>
<td>2, 1</td>
<td>26 weeks</td>
<td>Frequencies of overall AEs and target knee AEs comparable between groups; most frequent target knee AEs in all 3 groups: arthralgia, stiffness, swelling, effusion with no differences between groups; majority mild or moderate; no significant changes in vital signs, antibody testing results or lab safety concerns</td>
</tr>
<tr>
<td>Huang et al</td>
<td>200</td>
<td>K-L II-III</td>
<td>Hyalgan</td>
<td>Saline (Sa)</td>
<td>5</td>
<td>26 weeks</td>
<td>More patients in the placebo group experienced at least 1 AE (48% vs 39%); all mild-moderate, none considered related to study treatment; 5 serious AEs reported HA=3 vs S=2, all considered unrelated to study treatment; statistically significant change from baseline in platelet counts between groups at 5 weeks not felt to be clinically significant (p=0.027)</td>
</tr>
</tbody>
</table>
jubin injections may have structural benefit to cartilage, a long-held theory which has been supported by a recent study that links a decrease in synovial fluid hyaluronan molecular weight distribution with an increased risk of progressive cartilage loss in OA. Similarly, the benefit of HA injection on symptoms and/or osteoarthritic cartilage may or may not allow delay in total knee replacement surgery. Putative mechanisms through which HA may reduce OA progression include improved cartilage/synovial fluid rheology, increased synthesis of extracellular matrix constituents including better ‘quality’ HA, suppression of inflammatory mediators (eg, cytokines, prostaglandins, nitric oxide), reduction in fibronectin fragment-induced damage, and alteration in immune cell activity. HA-mediated chondroprotection has been demonstrated in animal, in vitro and clinical studies, including a recent article that found a decreased rate of medial and lateral tibial articular cartilage degeneration following HA injections through the use of a state-of-the-art, MRI-based assessment of cartilage integrity. Other studies of the structural impact of HA injections of similar design have, however, failed to demonstrate structural benefit to cartilage from one series of injections. Thus, for patients with knee OA, HA injections may offer benefits that extend beyond the issues of the statistical significance and clinical relevance of the symptomatic results that they eventuate.

We chose to analyse the data regarding HA injections for knee OA according to a novel temporal scheme. We compared the results for each treatment at the time of the maximal treatment efficacy across studies rather than selecting a consistent, single time from injection. Thus, the time at which data were assessed varied between some studies. When comparing HA to IAS, we used the time of optimal HA benefit for analysis of studies of HA versus IAS injections as our intent was to investigate whether HA injections had significant clinical efficacy at any time point. Our results suggest that maximal benefit occurs at different times following injection with HA and IAS. These results are consistent with prior systematic reviews that found superiority of IAS injection over HA injection from 0 to 4 weeks after administration but that also found that HA injection was superior to IAS from 4 to 26 weeks. In this regard, each injectable medication may have a different role in treating those with knee OA. Specifically, IAS may have utility to rapidly abort a flare of knee OA, where rapid onset is required as a bridge to additional treatment including physical therapy which might otherwise prove too painful. HA injections, contrarily, may be used to yield longer term control of baseline symptoms but may not be appropriate for the treatment of acute exacerbations given the longer time to onset of relief.

Our study has several limitations. We did not include unpublished trials, though we searched for these items, a factor which may bias towards the positive direction because of publication bias. However, the Egger value indicates that it is unlikely that publication bias exists. Further, the outcome measures, assessment times and study designs used in the included HA studies varied widely. Further, as OARSI responder rates were not collected in all trials, we compared only trials that collected these data in this portion of our analysis. We had access to study level data only, not individual patient data, and were thus unable to impute OARSI responses from other trials. Additionally, a wide variety of HA products of different structure and molecular weight are available, but we were unable to identify significant changes in efficacy related to these differences.

Finally, our study is unable to distinguish whether the accuracy of HA injection affects its efficacy, for example, whether the use of ultrasound guidance would improve the efficacy of HA
injections in knee OA. A recent review by the AMSSM finds that the ultrasound-guided (USG) injection in the knee is more accurate and that the USG IAS injection is more efficacious than the landmark-guided (LMG) injection.62 The significance of this difference for the IAS injection is unknown for HA injections, as we are unaware of any published trials comparing USG versus LMG injections of HA for knee OA. Our data may better approximate the results of those using LMG injections in clinical practice if indeed a difference in efficacy and accuracy with USG exists for HA injections.

CONCLUSION

In the light of the aforementioned results of our network-meta-analysis, the AMSSM recommends the use of HA for the appropriate patients with knee OA. Using The Grades of Recommendation, Assessment, Development and Evaluation Working Group system,13 there are multiple randomised controlled trials, indicating HIGH QUALITY evidence: “We RECOMMEND viscosupplementation injections for Kellgren and Lawrence (KL) grade II-III knee OA in those patients above the age of 60 years of age based on HIGH quality evidence demonstrating benefit using OMERACT-OARSI Responder Rating” but the evidence should be downgraded due to indirectness for those under 60 years of age, “We SUGGEST viscosupplementation injections for knee OA for those under the age of 60 years of age based on MODERATE quality evidence due to response of treatment in those over 60 years of age”. We also recommend that clinicians and researchers collect OMERACT-OARSI responder data to track individual response to the viscosupplementation. Further high quality studies are needed to address the residual uncertainties regarding the clinical benefit achieved from HA injections, especially in the active 40–60 year age group. Prediction rules are needed to identify patient characteristics that prospectively identify members of the subgroup of patients with OA who will demonstrate a more robust response to HA injections as opposed to those who are unlikely to benefit.

Competing interests None declared.

Provenance and peer review Not commissioned; internally peer reviewed.

REFERENCES

Consensus statement


AMSSM scientific statement concerning viscosupplementation injections for knee osteoarthritis: importance for individual patient outcomes

Thomas H Trojan, Andrew L Concoff, Susan M Joy, John R Hatzenbuehler, Whitney J Saulsberry and Craig I Coleman

doi: 10.1136/bjsports-2015-095683

Updated information and services can be found at:
http://bjsm.bmj.com/content/50/2/84

These include:

Supplementary Material

Supplementary material can be found at:
http://bjsm.bmj.com/content/suppl/2016/01/04/50.2.84.DC1

References

This article cites 58 articles, 16 of which you can access for free at:
http://bjsm.bmj.com/content/50/2/84#BIBL

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

Editor's choice (321)
Degenerative joint disease (239)
Musculoskeletal syndromes (431)
Osteoarthritis (117)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/